Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta‐analysis of a shifting treatment paradigm

Cancer 2026 Open access

Read full text
Authors: Salvatore Perrone, L. De Fazio, Sebastian Monachetti, Matteo Molica
DOI: 10.1002/cncr.70372
Cited by: 2
References: 28

Abstract

BACKGROUND: In younger, fit patients with acute myeloid leukemia (AML), intensive chemotherapy (IC) followed by consolidation or allogeneic hematopoietic stem cell transplantation (HSCT) is the standard approach. The authors performed a systematic review and meta-analysis to evaluate younger patients with AML treated with hypomethylating agents (HMA) plus venetoclax. METHODS: This systematic review and meta-analysis was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. MEDLINE and the Cochrane Library were systematically searched through February 2026. Studies included AML patients with a median age

Fields of Study & Subjects

Acute Myeloid Leukemia Research Epigenetics and DNA Methylation Amyotrophic Lateral Sclerosis Research

Publication details

Journal / source
Cancer
Publisher
Wiley
Volume
132
Issue
7
Pages
e70372–e70372
Publication date
31 March 2026
Language
EN